Recent research has shown that B3 could possibly be used as an
antifungal treatment. The research was
carried out by the Institute for Research in Immunology and Cancer (IRIC) of
the University of Montreal, led by Martine Raymond, Pierre Thibault, and Alain
Verreault (in conjunction with Alaka Mullick from the Biotechnology Research
Institute of the National Research Council Canada. This study was reported in Nature
Medicine. “Researchers found that genetic
or pharmacological inhibition of Hst3 with nicotinamide, a form of vitamin B3,
strongly reduced C. albicans virulence in a mouse model. Both normal and
drug-resistant strains of C. albicans were susceptible to nicotinamide. In
addition, nicotinamide prevented the growth of other pathogenic Candida species
and Aspergillus fumigatus (another human pathogen), thus demonstrating the
broad antifungal properties of nicotinamide.”
Thus if new therapies were developed to kill C. albicans this would help
since it is one of the main causes of infections patients pick up in hospitals
and is linked to high mortality rates.